BioMarin Pharmaceutical Inc

BioMarin’s FDA approval for PALYNZIQ in adolescents boosts its PKU market, spurring analyst praise and strong investor sentiment.

BioMarin’s FDA approval expands PALYNZIQ to 12‑year‑old PKU patients, boosting sales and analyst targets to $104—key for investors watching earnings and growth prospects.

BioMarin’s Amicus acquisition and Voxzogo’s sales surge give the company a cash‑flow base and high‑growth engine for rare‑disease therapy.

BioMarin’s $4.8 B acquisition of Amicus Therapeutics expands its lysosomal storage disease portfolio, boosting stock, options, and investor optimism.

BioMarin Pharmaceutical Inc. announced that its enzyme-replacement therapy, PALYNZIQ, achieved a 49.7% reduction in mean blood phenylalanine levels among adolescents with phenylketonuria in a Phase-3 study, marking a significant milestone for the co…

BioMarin Pharmaceutical Inc. exceeded market expectations in Q2 2025, reporting a revenue of $825 million and raising its full-year guidance to $3.125 billion.

BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma, expanding its enzyme therapy portfolio and positioning itself as a frontrunner in addressing rare diseases.